Journal Article

Tigecycline: what is it, and where should it be used?

David M. Livermore

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 56, issue 4, pages 611-614
Published in print October 2005 | ISSN: 0305-7453
Published online August 2005 | e-ISSN: 1460-2091 | DOI:
Tigecycline: what is it, and where should it be used?

Show Summary Details


Tigecycline is the first glycylcycline to be launched and is one of the very few new antimicrobials with activity against Gram-negative bacteria. It evades acquired efflux and target-mediated resistance to classical tetracyclines, but not chromosomal efflux in Proteeae and Pseudomonas. Cmax is low, but tissue penetration is excellent and the compound has shown equivalence to imipenem/cilastatin in intra-abdominal infection and to vancomycin plus aztreonam in skin and skin structure infection. Tigecycline may prove particularly useful for treatment of surgical wound infections, where both gut organisms and MRSA are likely pathogens. It is also likely to find a role in the treatment of infections due to multiresistant pathogens, including Acinetobacter spp. and ESBL producers, as well as MRSA and enterococci.

Keywords: tetracyclines; glycylcyclines; GAR-936

Journal Article.  2799 words.  Illustrated.

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.